Zometa Infusion

Zometa is an infusion that contains zoledronic acid, a bisphosphonate drug intended for bone strengthening.

This therapy is most commonly used in patients with bone metastases and in people with severe osteoporosis.

Zometa is administered intravenously under controlled conditions and works by slowing down bone tissue degradation.

The infusion is given periodically and has a long-lasting effect, which makes it practical for long-term therapy.

In addition to oncology patients, it is also used in people with Paget's disease and high calcium levels in the blood.

Zometa effectively reduces the risk of fractures and alleviates pain caused by bone damage.

The therapy is performed in the Medical Time day hospital, with constant supervision by a specialist doctor.

This infusion is part of the standard treatment for numerous malignant and non-malignant bone diseases.

Patients are given an individual approach depending on the primary diagnosis and general condition.

Zometa infusion at Medical Time is administered by doctors with many years of experience in internal medicine and oncology practice.

Preparation for Zometa infusion includes a detailed laboratory analysis, especially monitoring calcium levels and kidney function.

Before the infusion, the patient should be well-hydrated to reduce the risk of kidney damage.

The infusion is administered slowly, usually over 15 to 30 minutes, with constant medical supervision.

Before starting the therapy, the patient signs an informed consent form and receives all necessary information.

On the day of the infusion, a light meal is recommended, and exertion should be avoided after the treatment.

Zometa is not recommended for people with severe kidney damage without prior evaluation by a nephrologist.

The therapy is performed in a pleasant and safe environment at Medical Time hospital.

Medical staff monitors vital parameters before, during, and after drug administration.

If side effects occur, the therapy is immediately discontinued, and adequate measures are applied.

The patient receives instructions for behavior after the infusion and a follow-up appointment if necessary.

The main benefits of Zometa infusion are slowing down bone degradation and preventing pathological fractures.

The therapy significantly improves the quality of life for oncology patients with bone metastases.

Zometa reduces the need for analgesics and alleviates chronic bone pain.

The infusion contributes to the stabilization of blood calcium and reduces the risk of hypercalcemia.

In patients with osteoporosis, it improves bone density and reduces the fracture rate.

The single annual application provides high efficacy with a minimal number of visits.

The therapy is well-tolerated and has an advantage over oral bisphosphonates for many patients.

Zometa shows high efficacy in preventing complications of metastatic diseases.

At Medical Time, the infusion is administered according to the highest standards of safety and comfort.

Our team carefully monitors the progress of each patient and adjusts the treatment plan as needed.

Zometa is an important part of therapy for preventing serious complications in numerous chronic bone diseases.

The infusion is also used for preventive purposes in patients with a high risk of bone mass loss.

Along with a proper diet, calcium, and vitamin D intake, Zometa therapy yields the best results.

Doctors at Medical Time monitor the treatment's effectiveness and perform regular bone status check-ups.

The therapy is also suitable for elderly patients who have difficulty with oral medication administration.

Zometa infusion is often used as part of a multidisciplinary approach in oncology and rheumatology.

In combination with physical therapy, it can contribute to faster recovery in patients with fractures.

Our specialists create personalized treatment protocols for each individual patient.

Patients receive a detailed supplementation plan and lifestyle advice after the infusion.

Medical Time provides all the conditions for safe, effective, and modern Zometa infusion therapy.